Home›Cardiology› Orthostatic hypotension affects roughly 1 in 4 patients with heart failure, meta-analysis estimates
Orthostatic hypotension affects roughly 1 in 4 patients with heart failure, meta-analysis estimatesOne in Four Heart Failure Patients Experience Orthostatic Hypotension
European journal of internal medicinePublished November 5, 2026Study authors: Coscetta Federica, Corica Bernadette, De Mare Andrea, De Grazia Valeria, Iannibelli Giordana, Negri …PubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider screening for orthostatic hypotension in heart failure patients, as prevalence may be about 1 in 4.
This meta-analysis pooled data from 10 cohorts across 9 studies, including 2036 patients with heart failure, to estimate the prevalence of orthostatic hypotension (OH). The pooled prevalence was 26.7% (95% CI 20.4-34.2%), indicating that approximately 1 in 4 patients with heart failure may have OH. Between-study heterogeneity was high (I2=90.2%), and the authors also examined geographical variation in prevalence, though specific regional estimates were not reported.
The authors note that OH is common in heart failure patients and may complicate the management of guideline-directed medical therapy. However, the meta-analysis does not establish a causal link between heart failure and OH; it only provides a prevalence estimate. No information on adverse events, follow-up duration, or study settings was reported.
Key limitations include the high heterogeneity, which suggests substantial variability in prevalence estimates across studies, and the absence of reported funding or conflicts of interest. The certainty of the evidence was not formally assessed.
In practice, clinicians should be aware that OH is frequent in heart failure patients and consider screening for it, especially when titrating guideline-directed medical therapy. However, the high heterogeneity and observational nature of the included studies mean the estimate should be interpreted with caution and may not be generalizable to all heart failure populations.
How this fits prior evidence
This meta-analysis provides a prevalence estimate for orthostatic hypotension in heart failure, a comorbidity that may complicate the use of guideline-directed medical therapy. Prior coverage has focused on interventions such as IV albumin with furosemide to reduce worsening renal function to 25%, nurse-led telemonitoring to reduce heart failure readmissions, and exercise training to lower inflammatory biomarkers. None of these prior items addressed orthostatic hypotension. The new estimate of 26.7% (95% CI 20.4-34.2%) fills a gap by quantifying a common but underrecognized condition in heart failure, though the high heterogeneity (I2=90.2%) limits precision. It does not confirm or contrast with prior findings but extends the scope of heart failure management considerations.
A large review of data from 10 different groups found that orthostatic hypotension is common in people living with heart failure. This condition occurs when blood pressure drops significantly when a person changes positions, such as standing up from a sitting position. The study looked at over 2,000 patients to determine how often this happens.
The results showed that about 26.7% of patients with heart failure experience this drop in blood pressure. This means roughly one in four patients may deal with this issue. Because the study looked at many different groups, there was a lot of variation in the data between the different locations and groups studied.
It is important to know that this study only shows how common the condition is. It does not prove that heart failure causes the drop in blood pressure. However, because it is so common, it can make it harder for doctors to manage standard heart failure medications. Patients should talk to their doctors about how their blood pressure changes when they move.
What this means for you:
About 27% of heart failure patients experience a drop in blood pressure when standing up.
Common questions
How common is orthostatic hypotension in heart failure patients?
The study found that orthostatic hypotension is common in patients with heart failure. Specifically, the prevalence was found to be 26.7%. This means that approximately one in four patients with heart failure may experience a drop in blood pressure when changing positions.
Does heart failure cause a drop in blood pressure when standing?
The study does not establish a causal link between heart failure and orthostatic hypotension. It only provides the prevalence rate of how often the condition occurs in patients who already have heart failure.
Why does orthostatic hypotension matter for heart failure patients?
Because orthostatic hypotension is common, it can make it more difficult for doctors to manage guideline-directed medical therapy. Patients should discuss how their blood pressure changes when moving with their healthcare provider to manage their specific treatment plan.
BACKGROUND: Orthostatic hypotension (OH), defined as a reduction in systolic/diastolic blood pressure ≥20/10 mmHg upon standing, is common in older adults and may interfere with the optimization of guideline-directed medical therapy (GDMT) for Heart Failure (HF). However, the prevalence of OH in patients with HF has not been systematically quantified.
AIMS: To estimate the prevalence of orthostatic hypotension among patients with heart failure through a systematic review and meta-analysis.
METHODS: This study was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023420255). MEDLINE and EMBASE databases were systematically searched from inception to 31 December 2025. Studies reporting the prevalence of OH in HF populations with a sample size ≥100 patients were included. Pooled prevalence estimates with 95% confidence intervals (CI) were calculated, and heterogeneity was assessed using the I² statistic. Subgroup analyses were performed according to geographical location, study design, and clinical setting.
RESULTS: Nine studies (10 cohorts) including 2036 patients with HF were analyzed. The pooled prevalence of OH was 26.7% (95% CI 20.4-34.2%), indicating that approximately one in four HF patients presents this condition. Between-study heterogeneity was high (I²=90.2%). Subgroup analyses revealed higher prevalence in Europe and Asia and the Middle East compared with other countries.
CONCLUSIONS: HF is often burdened by OH which is common and found in 1 out 4 patients with HF and may complicate its management. Its impact on GDMT and clinical outcomes needs to be further investigated.
